Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
slaidlaw@well.ox.ac.uk

Research groups

Carroll Group: High Consequence Emerging Viruses Group

Stephen Laidlaw

PhD

Postdoctoral Research Scientist

I am a postdoc currently researching the immune response and antivirals against SARS-CoV2 and other coronaviruses.

Recent publications

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Journal article

Barnes E. et al, (2023), Nature medicine, 29, 1760 - 1774
A prototype lateral flow assay for detection of orthopoxviruses.
Journal article

Ulaeto DO. et al, (2022), The Lancet. Infectious diseases, 22, 1279 - 1280
Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
Journal article

Harvala H. et al, (2022), Transfusion, 62, 1347 - 1354
Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction.
Journal article

Guimond SE. et al, (2022), ACS central science, 8, 527 - 545
TRIM21/Ro52 - Roles in Innate Immunity and Autoimmune Disease
Journal article

Jones EL. et al, (2021), Frontiers in Immunology, 12

More publications